Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa

Journal of Clinical Virology

Volumn 58, Issue 4, 2013, Pages 696-702

  Hanisch, R A ^a,b   Sow, P S ^c   Toure, M ^c   Dem, A ^d   Dembele, B ^d   Toure, P ^d   Winer, R L ^a   Hughes, J P ^a   Gottlieb, G S ^e   Feng, Q ^f   Kiviat, N B ^f   Hawes, S E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Centre Hospitalier Universitaire Dakar   (Senegal)

^d UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD4 count; HIV; HPV; Human immunodeficiency virus; Human papillomavirus; Senegal

Indexed keywords

CD4 ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AFRICA; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS DETECTION; WART VIRUS;

ANTIRETROVIRAL; ARV; CD4 COUNT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CIN; DEOXYRIBONUCLEIC ACID; DNA; HIGH-RISK HUMAN PAPILLOMAVIRUS; HIV; HPV; HR-HPV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; SENEGAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; CERVIX UTERI; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENEGAL; YOUNG ADULT;

EID: 84888840994     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.10.012     Document Type: Article

References (54)

1. Koutsky L., Holmes K., Critchlow C., Stevens C., Paavonen J., Beckmann A., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992, 327(18):1272-1278.
2. Muñoz N., Bosch F.X., de Sanjosé S., Tafur L., Izarzugaza I., Gili M., et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992, 52(5):743-749.
3. Walboomers J., Jacobs M., Manos M., Bosch F., Kummer J., Shah K., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
4. Clifford G.M., Smith J.S., Aguado T., Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89(1):101-105.
5. Bosch F.X., de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003, (31):3-13.
6. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjosé S., Franceschi S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131(10):2349-2359.
7. Sun X., Kuhn L., Ellerbrock T., Chiasson M., Bush T., Wright T.J. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337(19):1343-1349.
8. Minkoff H., Feldman J., DeHovitz J., Landesman S., Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998, 178(5):982-986.
9. Ahdieh L., Muñoz A., Vlahov D., Trimble C., Timpson L., Shah K. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000, 151(12):1148-1157.
10. Jamieson D.J., Duerr A., Burk R., Klein R.S., Paramsothy P., Schuman P., et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002, 186(1):21-27.
11. Palefsky J. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003, 15(5):382-388.
12. Clifford G.M., Gonçalves M.A., Franceschi S., Group HaH.S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20(18):2337-2344.
13. Blossom D.B., Beigi R.H., Farrell J.J., Mackay W., Qadadri B., Brown D.R., et al. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol 2007, 79(6):758-765.
14. Rowhani-Rahbar A., Hawes S., Sow P., Toure P., Feng Q., Dem A., et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007, 196(6):887-894.
15. Grulich A., van Leeuwen M., Falster M., Vajdic C. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67.
16. Krishnan A., Levine A.M. Malignancies in women with HIV infection. Womens Health (Lond Engl) 2008, 4(4):357-368.
17. [CDC] CfDCaP. HIV Classification: CDC and;1; WHO Staging Systems. [accessed 18.01.13], 2013. http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/cg-205_hiv_classification.html.
18. Denny L., Boa R., Williamson A.L., Allan B., Hardie D., Stan R., et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008, 111(6):1380-1387.
19. Delmas M., Larsen C., van Benthem B., Hamers F., Bergeron C., Poveda J., et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression, European Study Group on Natural History of HIV Infection in Women. AIDS 2000, 14(12):1775-1784.
20. Taylor G., Wolff T., Khanna N., Furth P., Langenberg P. Genital dysplasia in women infected with human immunodeficiency virus. J Am Board Fam Pract 2004, 17(2):108-113.
21. Drogoul-Vey M.P., Marimoutou C., Robaglia-Schlupp A., Beerli M., Gastaut J.A., Cau P., et al. Determinants and evolution of squamous intraepithelial lesions in HIV-infected women, 1991-2004. AIDS Care 2007, 19(8):1052-1057.
22. Veldhuijzen N.J., Braunstein S.L., Vyankandondera J., Ingabire C., Ntirushwa J., Kestelyn E., et al. The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda. BMC Infect Dis 2011, 11:333.
23. Palefsky J.M., Minkoff H., Kalish L.A., Levine A., Sacks H.S., Garcia P., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91(3):226-236.
24. Singh D.K., Anastos K., Hoover D.R., Burk R.D., Shi Q., Ngendahayo L., et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009, 199(12):1851-1861.
25. Strickler H., Palefsky J., Shah K., Anastos K., Klein R., Minkoff H., et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003, 95(14):1062-1071.
26. Heitzinger K., Sow P.S., Dia Badiane N.M., Gottlieb G.S., N'Doye I., Toure M., et al. Trends of HIV-1, HIV-2 and dual infection in women attending outpatient clinics in Senegal, 1990-2009. Int J STD AIDS 2012, 23(10):710-716.
27. Zheng N.N., Kiviat N.B., Sow P.S., Hawes S.E., Wilson A., Diallo-Agne H., et al. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol 2004, 78(24):13934-13942.
28. Feng Q., Balasubramanian A., Hawes S.E., Toure P., Sow P.S., Dem A., et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst. 2005, 97(4):273-282.
29. Hawes S., Critchlow C., Sow P., Touré P., N'Doye I., Diop A., et al. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst 2006, 98(2):100-109.
30. Gottlieb G.S., Sow P.S., Hawes S.E., Ndoye I., Redman M., Coll-Seck A.M., et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002, 185(7):905-914.
31. Kuypers J.M., Critchlow C.W., Gravitt P.E., Vernon D.A., Sayer J.B., Manos M.M., et al. Comparison of dot filter hybridization, Southern transfer hybridization, and polymerase chain reaction amplification for diagnosis of anal human papillomavirus infection. J Clin Microbiol 1993, 31(4):1003-1006.
32. Weaver B.A., Feng Q., Holmes K.K., Kiviat N., Lee S.K., Meyer C., et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004, 189(4):677-685.
33. Ng'ayo M.O., Bukusi E., Rowhani-Rahbar A., Koutsky L.A., Feng Q., Kwena Z.A., et al. Epidemiology of human papillomavirus infection among fishermen along Lake Victoria Shore in the Kisumu District, Kenya. Sex Transm Infect 2008, 84(1):62-66.
34. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
35. Holmes R.S., Hawes S.E., Touré P., Dem A., Feng Q., Weiss N.S., et al. HIV infection as a risk factor for cervical cancer and cervical intraepithelial neoplasia in Senegal. Cancer Epidemiol Biomarkers Prev 2009, 18(9):2442-2446.
36. De Vuyst H., Lillo F., Broutet N., Smith J. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008, 17(6):545-554.
37. Meys R., Gotch F.M., Bunker C.B. Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?. Br J Dermatol 2010, 162(1):6-11.
38. Strickler H., Burk R., Fazzari M., Anastos K., Minkoff H., Massad L., et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005, 97(8):577-586.
39. Theiler R.N., Farr S.L., Karon J.M., Paramsothy P., Viscidi R., Duerr A., et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010, 115(6):1150-1158.
40. Dartell M., Rasch V., Kahesa C., Mwaiselage J., Ngoma T., Junge J., et al. Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study. Sex Transm Dis 2012, 39(3):201-208.
41. Firnhaber C., Zungu K., Levin S., Michelow P., Montaner L.J., McPhail P., et al. Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol 2009, 53(1):10-17.
42. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006, 19(1):99-105.
43. Massad L., Riester K., Anastos K., Fruchter R., Palefsky J., Burk R., et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999, 21(1):33-41.
44. La Ruche G., Leroy V., Mensah-Ado I., Ramon R., You B., Bergeron C., et al. Short-term follow up of cervical squamous intraepithelial lesions associated with HIV and human papillomavirus infections in Africa. Int J STD AIDS 1999, 10(6):363-368.
45. Fitzgerald D.W., Bezak K., Ocheretina O., Riviere C., Wright O., Milne G.L., et al. The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) 2012, 5(1):34-40.
46. Desruisseau A.J., Schmidt-Grimminger D., Welty E. Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa. Infect Dis Obstet Gynecol. 2009, 2009:810596.
47. Mbulawa Z.Z., Marais D.J., Johnson L.F., Boulle A., Coetzee D., Williamson A.L. Influence of human immunodeficiency virus and CD4 count on the prevalence of human papillomavirus in heterosexual couples. J Gen Virol 2010, 91(Pt 12):3023-3031.
48. Xi L., Touré P., Critchlow C., Hawes S., Dembele B., Sow P., et al. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 2003, 103(6):803-809.
49. Harper D., Franco E., Wheeler C., Ferris D., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765.
50. Ault K.A. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 2007, 107(2 Suppl. 1):S31-S33.
51. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008, 110(3 Suppl. 1):S18-S25.
52. Langley C.L., Benga-De E., Critchlow C.W., Ndoye I., Mbengue-Ly M.D., Kuypers J., et al. HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women. AIDS 1996, 10(4):413-417.
53. Ahdieh-Grant L., Li R., Levine A., Massad L., Strickler H., Minkoff H., et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004, 96(14):1070-1076.
54. Fife K., Wu J., Squires K., Watts D., Andersen J., Brown D. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 51(3):274-282.